Drugs / Levoleucovorin
Levoleucovorin
also known as
Calcium levofolinate · Levofolinate · Levofolinic Acid · L-folinic acid · Isovorin · l-LV · levofolinate calcium · Levoleucovorin Calcium · +5 more
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | FUSILEV | — | 2011-04-29 | fda.gov ↗ |
| Approved | US (FDA) | FUSILEV | — | 2008-03-07 | fda.gov ↗ |
Trials 31
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06538207 | Jan 2021 → Oct 2024 | malignant pancreatic neoplasm | Ono Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06780111 | Jul 2025 → Jan 2032 expected | esophageal squamous cell carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06428409 | Jun 2024 → Oct 2029 expected | biliary tract cancer, colorectal cancer, pancreatic ductal adenocarcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05319639 | Feb 2023 → Oct 2024 overdue | gastric cancer | Fujian Cancer Hospital | Recruiting | No outcome recorded |
| Phase 222 trials | ||||||
| Phase 2 | NCT07621497 | Jun 2026 → Jun 2029 expected | metastatic malignant neoplasm in the colon | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07061080 | Dec 2025 → Sep 2026 | neuroendocrine carcinoma | Spanish Group for Research in Neuroendocrine Tumors | Terminated | No outcome recorded |
| Phase 2 | NCT07559760 | Nov 2025 → May 2027 expected | colorectal cancer | The First Hospital of Jilin University | Recruiting | No outcome recorded |
| Phase 2 | NCT07119931 | Sep 2025 → Dec 2027 expected | hepatocellular carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07018570 | Jul 2025 → Jun 2030 expected | gastroesophageal junction adenocarcinoma | National Cancer Center Hospital East | Recruiting | No outcome recorded |
| Phase 2 | NCT06607107 | Feb 2024 → Jan 2026 overdue | hepatocellular carcinoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06197438 | Jan → Apr 2024 | gastric cancer | Fujian Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05715931 | May 2023 → Feb 2026 overdue | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Yu jiren | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05797883 | Aug 2022 → Dec 2023 | colorectal cancer | China Medical University, China | Unknown | No outcome recorded |
| Phase 2 | NCT04745988 | Nov 2021 → Aug 2026 overdue | gastric cancer | National Cancer Center Hospital East | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05582278 | Jan 2021 → Jan 2024 | hepatocellular carcinoma | Wen Li | Unknown | No outcome recorded |
| Phase 2 | NCT05673772 | Oct 2020 → Dec 2028 expected | rectal cancer | Kyungpook National University Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04060030 | Oct 2020 → Jul 2026 overdue | autism spectrum disorder, language disorder | Southwest Autism Research & Resource Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04060017 | Sep 2020 → Jul 2026 overdue | autism spectrum disorder, language disorder | Southwest Autism Research & Resource Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03698461 | May 2019 → Dec 2021 | colonic neoplasm, metastatic neoplasm, rectal neoplasm | Asan Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT03788174 | Feb → Dec 2019 | gastric adenocarcinoma | Fujian Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03707639 | Nov 2018 → Oct 2019 | gastric adenocarcinoma | Fujian Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03301454 | Aug 2018 → Jul 2022 | esophageal squamous cell carcinoma | Centre Oscar Lambret | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03528785 | Mar 2018 → Nov 2021 | pancreatic adenocarcinoma | Centro Ricerche Cliniche di Verona | Unknown | No outcome recorded |
| Phase 2 | NCT02497157 | May 2015 → Jun 2019 | colorectal cancer | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | Completed | No outcome recorded |
| Phase 2 | NCT02000050 | Oct 2013 → Mar 2019 | rectal carcinoma | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Completed | No outcome recorded |
| Phase 2 | NCT01652196 | Nov 2012 → Aug 2019 | colon mucinous adenocarcinoma, colon signet ring cell adenocarcinoma, rectal signet ring cell adenocarcinoma, rectum mucinous adenocarcinoma | John Hays | Completed | No outcome recorded |
| Phase 34 trials · 1 met primary | ||||||
| Phase 3 | NCT06509126 | Jun 2024 → Jan 2028 expected | colorectal cancer | National Cancer Institute, Naples | Recruiting | No outcome recorded |
| Phase 3 | NCT01926236 | Feb 2014 → Jan 2018 | ampulla of vater cancer, cholangiocarcinoma, gallbladder cancer | The Christie NHS Foundation Trust | Completed | Met primary |
| Phase 3 | NCT00195585 | Oct 2002 → Feb 2006 | colon carcinoma | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00195572 | May 2002 → Aug 2008 | gastric cancer | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04174339 | Dec 2019 → Dec 2020 | gastric adenocarcinoma | Fujian Cancer Hospital | Unknown | No outcome recorded |
| Comparator or background therapy73 trials | ||||||
| Phase 1 | NCT05546853 Background | Mar 2023 → Dec 2024 | pancreatic ductal adenocarcinoma | University Hospital, Grenoble | Completed | No outcome recorded |
| Phase 1 | NCT05087992 Background | Nov 2021 → Oct 2023 | digestive system cancer | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT06540261 Background | Sep 2021 → Dec 2027 expected | colorectal cancer | Ono Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06532344 Background | Jul 2021 → Jun 2027 expected | malignant pancreatic neoplasm | Ono Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03798626 Background | May 2019 → Mar 2023 | colorectal cancer, gastroesophageal cancer, renal cell carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT03597581 Background | Jun 2018 → Mar 2025 | colorectal carcinoma, gastric cancer | Inspirna, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03244774 Background | Jan → Dec 2018 | gastric adenocarcinoma | Fujian Cancer Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT03343301 Background | Nov 2017 → Jan 2019 | gastric cancer | Five Prime Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02641873 Background | Dec 2015 → Dec 2016 | colorectal cancer | Sumitomo Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02468557 Background | Jul 2015 → Apr 2016 | pancreatic ductal adenocarcinoma | Gilead Sciences | Terminated | No outcome recorded |
| Phase 1 | NCT01286818 Background | Feb 2011 → Feb 2012 | colorectal carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1/2 | NCT06469944 Background | Sep 2024 → Sep 2029 expected | esophageal cancer, gastroesophageal adenocarcinoma, gastroesophageal junction adenocarcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05609370 Background | Jan 2023 → May 2025 overdue | colorectal cancer | BeiGene | Active not recruiting | Missed primary |
| Phase 1/2 | NCT05438459 Background | Jun 2022 → Mar 2032 expected | gastric cancer, malignant pancreatic neoplasm | Kyushu University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03294252 Background | May 2017 → Feb 2019 | digestive system cancer | Institut Cancerologie de l'Ouest | Terminated | No outcome recorded |
| Phase 1/2 | NCT01681472 Comparator | Sep 2012 → Aug 2013 | colonic neoplasm | Isofol Medical AB | Completed | Mixed |
| Phase 1/2 | NCT01611857 Background | Jul 2012 → Jul 2015 | gastroesophageal cancer | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 2 | NCT07793942 Background | Oct 2026 → Sep 2028 expected | cancer | Merck Sharp & Dohme LLC | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07381400 Background | Feb 2026 → Feb 2028 expected | rectal cancer | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06790706 Background | Oct 2025 → Nov 2028 expected | carcinoid tumor, digestive system neuroendocrine neoplasm, gestational trophoblastic neoplasm, peritoneal mesothelioma +2 | Hospices Civils de Lyon | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07124884 Background | Aug 2025 → Jun 2030 expected | acute myeloid leukemia, KRAS gene mutation, colorectal carcinoma | Federation Francophone de Cancerologie Digestive | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06317662 Background | Jun 2025 → Dec 2028 expected | B-cell acute lymphoblastic leukemia, acute leukemia of ambiguous lineage | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT06757244 Background | Feb 2025 → Feb 2028 expected | pancreatic neoplasm | Hopital Foch | Recruiting | No outcome recorded |
| Phase 2 | NCT06225999 Background | Apr 2024 → Apr 2025 | pancreatic adenocarcinoma | Servier | Completed | No outcome recorded |
| Phase 2 | NCT05839470 Background | Nov 2023 → Mar 2024 | colorectal cancer | Fujian Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05945823 Background | Jul 2023 → Oct 2026 expected | esophageal adenocarcinoma, esophageal squamous cell carcinoma, gastroesophageal cancer, malignant pancreatic neoplasm | Taiho Oncology, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05712356 Background | May 2023 → Apr 2026 | gallbladder carcinoma, intrahepatic cholangiocarcinoma | Lisata Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04952753 Background | Nov 2021 → Jan 2025 | colorectal cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT05312398 Background | Jul 2021 → Aug 2026 overdue | colorectal adenocarcinoma | University of Campania Luigi Vanvitelli | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04121039 Comparator | Dec 2019 → Dec 2021 | gastric adenocarcinoma | Fujian Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04310176 Background | May 2019 → Dec 2023 | colorectal cancer | National Cancer Institute, Naples | Unknown | No outcome recorded |
| Phase 2 | NCT03719924 Background | Mar 2019 → Apr 2024 | squamous cell carcinoma | Federation Francophone de Cancerologie Digestive | Completed | Missed primary |
| Phase 2 | NCT03694522 Background | Sep 2018 → Sep 2020 | gastric cancer | Five Prime Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02820857 Comparator | Sep 2017 → Aug 2022 | neuroendocrine carcinoma | Hospices Civils de Lyon | Completed | No outcome recorded |
| Phase 2 | NCT03222089 Background | Jul 2017 → Jul 2019 | metastatic malignant neoplasm in the colon | Fujian Cancer Hospital | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02697838 Background | Aug 2016 → Mar 2018 | gastric cancer | Fujian Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02697058 Comparator | Mar 2016 → May 2017 | malignant pancreatic neoplasm | Servier | Completed | No outcome recorded |
| Phase 2 | NCT02337946 Background | Oct 2014 → Mar 2017 | colorectal carcinoma | Takeda | Completed | Missed primary |
| Phase 2 | NCT01882868 Background | Jul 2013 → Aug 2015 | colorectal cancer | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT01590719 Background | Jul 2012 → Oct 2014 | gastric cancer | Hoffmann-La Roche | Completed | Missed primary |
| Phase 2 | NCT01383707 Background | Aug 2011 → May 2014 | colorectal cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT01111604 Background | Aug 2010 → Dec 2013 | colon carcinoma, rectal carcinoma | Eli Lilly and Company | Completed | Missed primary |
| Phase 2 | NCT00865709 Background | Mar 2009 → Jan 2011 | colorectal cancer | Bayer | Completed | Missed primary |
| Phase 2 | NCT00609622 Background | Apr 2008 → Jul 2011 | colorectal neoplasm | Pfizer | Terminated | Missed primary |
| Phase 2 | NCT01481545 Background | Dec 2006 → Jul 2011 | rectal cancer | National Cancer Institute, Naples | Completed | No outcome recorded |
| Phase 2/3 | NCT06509880 Comparator | Jul 2022 → Jul 2023 | — | MIPO Clinic | Completed | No outcome recorded |
| Phase 2/3 | NCT05179889 Background | Jul 2021 → Jul 2028 expected | malignant colon neoplasm | Chungnam National University Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03686254 Comparator | Jul 2018 → Oct 2023 | colorectal cancer | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT07818070 Background | Feb 2027 → Jan 2031 expected | esophageal adenocarcinoma, gastric cancer, gastroesophageal cancer | Ono Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07676162 Background | Aug 2026 → Sep 2029 expected | colorectal cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07582315 Comparator | Jul 2026 → Dec 2028 expected | biliary tract cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07606599 Comparator | May 2026 → Dec 2028 expected | biliary tract cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06793917 Background | Jun 2025 → Apr 2028 expected | gastric cancer | Fujian Cancer Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06750094 Background | Dec 2024 → Dec 2027 expected | colorectal neoplasm | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT06662786 Background | Oct 2024 → Dec 2028 expected | colorectal cancer | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT06041477 Background | Oct 2023 → Jul 2027 expected | chemotherapy-induced toxicity, hepatocellular carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT05768503 Comparator | Mar 2023 → Jan 2026 overdue | colorectal cancer | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT05253651 Background | Oct 2022 → Dec 2027 expected | colorectal neoplasm | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT04949256 Background | Jul 2021 → May 2025 | esophageal squamous cell carcinoma | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 3 | NCT04776655 Background | Apr 2021 → May 2025 overdue | colorectal cancer | Azienda USL Reggio Emilia - IRCCS | Recruiting | No outcome recorded |
| Phase 3 | NCT04662710 Background | Dec 2020 → Oct 2024 | gastroesophageal adenocarcinoma | Merck Sharp & Dohme LLC | Completed | Mixed |
| Phase 3 | NCT04456699 Comparator | Aug 2020 → Mar 2023 | colorectal cancer | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 3 | NCT04210115 Background | Feb 2020 → Jan 2026 overdue | esophageal adenocarcinoma, esophageal squamous cell carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03007147 Background | Aug 2017 → Jun 2026 overdue | B-cell acute lymphoblastic leukemia, T-cell acute lymphoblastic leukemia, mixed phenotype acute leukemia | Children's Oncology Group | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02563002 Comparator | Nov 2015 → Feb 2021 | colorectal carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT02394795 Background | May 2015 → Jan 2022 | colorectal cancer | Takeda | Completed | Met primary |
| Phase 3 | NCT01718873 Background | May 2012 → Dec 2015 | colorectal cancer | National Cancer Institute, Naples | Completed | Missed primary |
| Phase 3 | NCT01878422 Background | Nov 2007 → Mar 2014 | colorectal cancer | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Completed | Missed primary |
| Phase 3 | NCT00316745 Comparator | Apr 2006 → Mar 2009 | colorectal cancer | Hokkaido Gastrointestinal Cancer Study Group | Suspended | No outcome recorded |
| Phase 3 | NCT01524094 Comparator | Jun 2003 → Dec 2010 | peritoneal carcinomatosis | Uppsala University | Completed | No outcome recorded |
| — | NCT05601323 Background | Jan 2023 → May 2027 expected | pancreas disorder | SONIRE Therapeutics Inc. | Active not recruiting | No outcome recorded |
| — | NCT03904043 Background | Jul 2020 → Aug 2024 | rectum adenocarcinoma | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT03045770 Background | Feb 2017 → Dec 2019 | gastroesophageal junction adenocarcinoma | Fujian Cancer Hospital | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-11-20 | Ono Pharmaceutical Co., Ltd. | Regulatory Ono Receives Supplemental Approval of Combination Therapy with BRAFTOVI® Capsule, a BRAF Inhibitor, for the Indication of Colorectal Cancer ono-pharma.com ↗ |
| 2018-11-21 | Upsher-Smith Laboratories | Regulatory MHLW Approves New Indication for LEVOFOLINATE I.V. Infusion upsher-smith.com ↗
This approval expands the indication of LEVOFOLINATE I.V. Infusion 25 mg [SAWAI] and 100 mg [SAWAI] to include the same uses as their brand equivalents. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-11-20 | Ono Pharmaceutical Co., Ltd. | Ono Receives Supplemental Approval of Combination Therapy with BRAFTOVI® Capsule, a BRAF Inhibitor, for the Indication of Colorectal Cancer ono-pharma.com ↗ |
| 2018-11-21 | Upsher-Smith Laboratories | MHLW Approves New Indication for LEVOFOLINATE I.V. Infusion upsher-smith.com ↗ |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 104 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Levoleucovorin | “This regimen consists of levoleucovorin 200 milligram/meter per square (mg/m\^2) or racemic leucovorin 400 mg/m\^2, oxaliplatin 85 mg/m\^2, bolus 5-fluorouracil 400 mg/m\^2,...” NCT02468557 ↗45“Forty-one participants will receive the treatment NALIRIFOX (liposomal irinotecan, 5-fluorouracil, levoleucovorin and oxaliplatin) until progression or unacceptable toxicity.” PMID 39987459 ↗ Feb 2025 “200 mg/m2 (Or levoleucovorin 100 mg/m2. If leucovorin is not available due to drug shortages the regimen should be administered with the leucovorin omitted) IV over 2 hours.” NCT01652196 ↗ “5-fluorouracil \[continuous infusion\], leucovorin \[administered IV\] (or levoleucovorin \[administered IV\]), and oxaliplatin \[administered IV\]” NCT04952753 ↗ “Oxaliplatin 85 mg/m2, Levoleucovorin 200mg (or Leucovroin, Leucosodium 400mg)/m2, 5- FU 400 mg/m2, and continuous 5- FU 2,400 mg/m2 for 46 hours” NCT05673772 ↗ “in combination with leucovorin or levoleucovorin (LV) IV administered per local guidelines and/or prescribing information once every 2 weeks” NCT05609370 ↗ “The LV5FU2 regimen includes folinic acid (400 mg/m², or 200 mg/m² if levo-leucovorin is used) as a two-hour IV infusion” NCT07124884 ↗ “Leucovorin 400 mg/m² IV infusion over 120 minutes, or 200 mg/m² levo-leucovorin if leucovorin is unavailable” NCT03343301 ↗ “Levofolinic Acid For Injection is the first approved class 2.1 sodium levoleucovorin formulation in China.” NCT07621497 ↗ “oxaliplatin 85 mg/ m\^2 + leucovorin 400 mg/ m\^2 (or 200 mg/ m\^2 levo-leucovorin) as a 2-hr IV infusion” NCT00609622 ↗ “Leucovorin day 1 every 14 days. Levoleucovorin may be substituted if leucovorin is not available.” NCT03904043 ↗ |
| Known as | Calcium levofolinate | “Treatment with LV5FU2 (5-FU, Calcium Levofolinate) - paclitaxel, regular tumor evaluation, best supportive care Other authorized treatment : usual paclitaxel pre-treatment...” NCT03301454 ↗18“The treatment option for the standard second-line FOLFIRI + bevacizumab therapy group is bevacizumab 5 mg/kg IV Drip Q2W, irinotecan 180 mg/m2 IV Drip Q2W, calcium folinate 400...” NCT05768503 ↗ “mFOLFOX7(Oxaliplatin 85mg/m2, Calcium Levofolinate 200mg/m2, Fluorouracil 400 mg/m2 D1，2400mg/m2 maintain 46 hours，) combined with Apatinib and Camrelizumab 200mg every 3 weeks.” NCT06607107 ↗ “The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).” NCT03244774 ↗ “The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).” NCT02697838 ↗ “The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).” NCT04121039 ↗ “folinic acid 400 mg/m2 or calcium levofolinate 200 mg/m2 given as a 2-h IV infusion” NCT06757244 ↗ “followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).” NCT03788174 ↗ “Calcium folinatc 400 mg/m2 or Calcium Levofolinate 200 mg/m2 D1” NCT03686254 ↗ “calcium levofolinate, 200 mg/m2 infusion for 1 hours” NCT05582278 ↗ “and Calcium Levofolinate (200 mg/m2)” NCT03707639 ↗ |
| Known as | Isovorin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00316745 ↗ |
| Known as | L-folinic acid | “oxaliplatin 85 mg/m² and l-folinic acid 200 mg/m² or d,l-folinic acid 400 mg/m² concurrently, as a 2-hour IV infusion” NCT05712356 ↗7“Folinic acid: 400 mg/m² intravenous over 30 minutes or L-folinic acid (racemic form L) 200 mg/m² over 30 minutes” NCT03719924 ↗ “FOLFIRI: 200 mg L-folinic acid given concurrently with 180 mg/ m² irinotecan over 1.30 h IV infusion” NCT05312398 ↗ “L-Folinic acid 100 mg/m2 IV infusion of 2 hours” NCT01878422 ↗ “L-folinic acid 200 mg/m2 IV” NCT06790706 ↗ |
| Known as | l-LV | “oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab” NCT02394795 ↗2“oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab” NCT02337946 ↗ “Levofolinate calcium (l-LV)” NCT02497157 ↗ |
| Known as | Leucosodium | “Levoleucovorin 200mg (or Leucovroin, Leucosodium 400mg)/m2” NCT05673772 ↗ |
| Known as | Leucovroin | “Levoleucovorin 200mg (or Leucovroin, Leucosodium 400mg)/m2” NCT05673772 ↗ |
| Known as | Levofolinate | “Patients were randomly assigned (1:1; block size of three), without stratification, to receive FOLFIRI (irinotecan 180 mg/m2, calcium folinate 400 mg/m2 or levofolinate 200...” PMID 36739879 ↗ Feb 202311“400 mg/m2 folinic acid or 200 mg/m² levofolinate in a 2-h infusion” NCT07061080 ↗ “Nanoliposomal irinotecan, Fluorouracil, Levofolinate” NCT05601323 ↗ “Levofolinate 100 mg/m2 iv: day 1-2” NCT02000050 ↗ |
| Known as | levofolinate calcium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02394795 ↗ |
| Known as | Levofolinic Acid | “Levo-folinic acid (LFA) will be allowed as a substitute for FA in the mFOLFOX-6 chemotherapy regimen” NCT01111604 ↗9“followed by levo-folinic acid 200 mg/m2 as 1- 2 hours i.v. infusion followed by i.v bolus.” NCT04310176 ↗ “Levofolinic Acid 200mg/m² continuous mixed infusion” NCT05797883 ↗ |
| Known as | Levofolinic Acid For Injection | “Levofolinic Acid For Injection is the first approved class 2.1 sodium levoleucovorin formulation in China.” NCT07621497 ↗ |
| Known as | Levoleucovorin Calcium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04060030 ↗ |
| Known as | LFA | “Levo-folinic acid (LFA) will be allowed as a substitute for FA in the mFOLFOX-6 chemotherapy regimen” NCT01111604 ↗ |
| Known as | Zuoyu | “Levofolinic Acid (Zuoyu ®)” NCT05797883 ↗ |
| Route | Intravenous | “200 mg/ m\^2 levo-leucovorin) as a 2-hr IV infusion” NCT00609622 ↗ |